In a recent phase 1 trial, intratumoral immunotherapy with pembrolizumab and mRNA-2752, a lipid nanoparticle-encapsulated mRNA encoding three immunomodulatory proteins, OX40L, interleukin (IL)-23, and IL-36γ, was tested in patients with ductal carcinoma in situ (DCIS) [83]. The gene discussed is IL36G; the disease is ductal breast carcinoma in situ.